Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

The Senate confirms Lee Zeldin to lead the E.P.A. The Justice Dept. seeks to have criminal charges dismissed against a former Republican representative. Trump signs Laken Riley Act, a law to make ...

Kennedy once again betrays his ignorance about Medicaid. “The premiums are too high, the deductibles are too high, and everybody’s getting sicker,” he said. But Medicaid has no premiums or ...

Bamlanivimab and etesevimab combination has been authorised under Emergency Use Authorisation in the US and select EU countries for the treatment of the disease.

Bank of Canada cuts key rate 0.25% but warns of tariff uncertainty Bank of Canada cuts key rate 0.25% but warns of tariff uncertainty The quarter-point reduction marks a step down from the Bank of ...